Figure 1: Heterogeneous expression of miR-1246 and miR-1290 in human NSCLC. | Nature Communications

Figure 1: Heterogeneous expression of miR-1246 and miR-1290 in human NSCLC.

From: Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression

Figure 1

(a) Tumour-formation efficiency of patient-derived tumour cell populations in NSG mice. T166+ or T166−, patient-derived CD166+ or CD166− sorted tumour cells. T166+, T166− and TS were generated from three patients. (b) Limiting dilution analysis of secondary tumour initiation by CD166+ and CD166− cells from primary xenograft tumours. Number of xenografted tumours formed and number of cells injected are shown. n=3 patient samples. (c) Intersection of miRNAs enriched in lung TICs (TS and T166+) compared with non-TICs (NHBE, SAEC and T166−) by miRNA microarray. Two panels with downregulated and upregulated miRNAs lists are shown. n=3. (d) qRT–PCR analysis of both miR-1246 and miR-1290 in non-tumorigenic cells (NHBE, SAEC and T166−) and TICs (T166+ and TS). n=3. (e) qRT–PCR analysis of miR-1246 and miR-1290 levels by box plot in paired tumour and normal tissues in NSCLC. The median values for miR-1246 and miR-1290 levels in normal tissues were normalized as 1; n=11. Differences between groups were analysed using unpaired t-tests. (f) Expression levels of miR-1246 in normal (N) and tumour (T) tissues across human lung adenocarcinoma (LUAD) and lung squamous carcinoma (LUSC) using TCGA miRNA-Seq data. Differences between groups were analysed using unpaired t-tests. n=521 (LUAD), n=504 (LUSC). (g) ISH for miR-1246 in primary lung adenocarcinoma. The staining intensity was classified as low/absent (0) and high (1+, 2+ and 3+). Both the staining intensity and number of tumours are shown. Scale bar, 50 μm. (h) Cumulative incidence estimates on the effect of miR-1246 and miR-1290 expression, as determined by ISH, on NSCLC mortality. The effect estimate was quantified in terms of the subdistribution hazard ratio and its associated 95% confidence interval (CI). The P values were calculated using log-rank tests; n=143. (i) Staining CD166 (immunohistochemistry, left) and miR-1246 (ISH, right) on serial sections of tumour and normal lung tissues. Scale bar, 50 μm. Data are represented as the mean±s.e.m. RQ, relative quantification; TS, patient-derived tumourspheres.

Back to article page